Reconova Biotech Secures Hundreds of Millions in Series C Funding with a Flavor Compound Solution Platform Focused on Natural Ingredients | Exclusive by 36Kr

36Kr learned that Ruifen Biotech, an enterprise in the field of synthetic biology, has completed a C-round financing worth hundreds of millions of yuan. This round of financing was led by Xingxiang Capital, with Ruipeng Xiangyu Fund participating as a follow-on investor. The raised funds will be used for commercial expansion and the construction of new production capacity. EC Capital served as the exclusive financial advisor for this round of financing.

In recent years, influenced by new health consumption concepts such as rich nutrition, pursuit of naturalness, and reduction of burdens, leading food enterprises and emerging brands have increasingly diverse demands for raw materials and ingredients. How to build innovative formulas around core raw materials and assist them in occupying more market share and enhancing brand influence by providing innovative solutions has become an important issue that upstream raw material suppliers urgently need to address.

Ruifen Biotech was founded in 2007 and is committed to pursuing pure, efficient, and clean natural ingredient preparation technologies to promote the sustainable development of natural raw materials. The founder, chairman, and CEO, Wang Xiaoyun, graduated from Zhejiang University and has nearly 20 years of experience in the industrial transformation of plant extracts and natural sweeteners.

Wang Xiaoyun believes that natural ingredient raw material suppliers are facing an overall upgrade. Suppliers should continuously evolve and have the ability to build innovative solutions that combine "taste, function, application, appearance, and cost" around core raw materials. Based on this, Ruifen Biotech has built three product platforms: the natural sweetener platform, the natural functional platform, and the pharmaceutical excipient platform, based on plant extraction and synthetic biology technologies.

It is reported that Ruifen Biotech has now cooperated with several leading scientific research institutions to form a stable network for the industrialization of scientific and technological achievements. The erythritol and allulose jointly developed by the company with the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences and the State Key Laboratory of Microbial Metabolism at Shanghai Jiao Tong University have been industrialized.

Among them, allulose is a rare sugar found in fruits such as figs and raisins. It has a sweetness of about 70% of that of sucrose, low calories, and has been recognized as GRAS (Generally Recognized as Safe) by the US FDA. It has been approved for use in many countries and regions around the world. In the second half of this year, allulose was approved for use as a food additive in China. In December 2025, Ruifen Biotech officially obtained the food production license for D-allulose and is one of the domestic enterprises capable of producing allulose in a compliant and large-scale manner.

Meanwhile, Ruifen Biotech is deeply involved in plant extraction technology and strives to make breakthroughs in multiple fields such as the stability of natural products, natural innovative flavors, and research on natural active ingredients.

Wang Xiaoyun believes that the core advantage of Ruifen Biotech lies in "the ability to transform biotechnology into market applications that address pain points." Based on insights into consumer trends, the company can provide customers with full-process solutions from raw materials to customized formulas to help them quickly seize the health consumption market.

"Currently, our compounding solutions have been verified by the market. We have successively provided core ingredients and key technical solutions for the products of more than 50 domestic and foreign enterprises, including Swisse, Yili, and Yuanqi Forest," said Wang Xiaoyun.

"We hope to continuously create new food formulas for various traditional or emerging brands with our raw material development, formula development, and formula implementation capabilities," Wang Xiaoyun said.

From a product perspective, data provided by Ruifen Biotech shows that the "revenue from innovative compounding solutions with functional sugar alcohols as the core and plant natural ingredients as supplements is growing rapidly."

It is also learned that Ruifen Biotech has also laid out an animal health platform for early technology reserves. In the future, it will provide products such as animal nutrition and animal protection for large feed groups and breeding enterprises.

In terms of production capacity layout, Ruifen Biotech has now established three production bases in Yangling, Shaanxi; Chuzhou, Anhui; and Hohhot, Inner Mongolia, to build a quality control system and supply network from raw materials to finished products. Among them, the first-phase construction of the biosynthetic production base of the Hohhot project under construction is planned to invest 300 million yuan.

Wang Xiaoyun said, "In the future, Ruifen Biotech will continue to strengthen its technological foundation, empower the global food industry, and bring healthier, more nutritious, and greener compound flavor solutions to consumers."